What actually helps social anxiety? One therapy sits above the rest
The largest network meta-analysis of social anxiety disorder ranked 41 options against each other. Individual CBT came out on top, and it was one of only two treatments to clearly beat a placebo.
| Group | Value (value) |
|---|---|
| Individual CBT | 1.19 (0.81 to 1.56) |
| MAOIs | 1.01 (0.45 to 1.56) |
| Benzodiazepines | 0.96 (0.36 to 1.56) |
| Group CBT | 0.92 (0.51 to 1.33) |
| SSRIs and SNRIs | 0.91 (0.6 to 1.23) |
If you want the single best-supported answer, it is individual cognitive behavioural therapy. In the largest head-to-head comparison ever done for social anxiety disorder, one-to-one CBT produced the biggest effect of any treatment tested, and it was one of only two interventions that outperformed not just a waitlist but a credible placebo [s1]. That is a stronger claim than the field can usually make, and it is worth understanding what sits behind it.
The comparison that ranked everything
The reference point is a systematic review and network meta-analysis published in The Lancet Psychiatry in 2014 [s1]. Its authors pooled 101 trials with 13,164 participants, covering 41 different interventions or control conditions grouped into 17 classes, drawn from published and unpublished research between 1988 and September 2013 [s1]. A network meta-analysis lets treatments that were never tested against each other directly be compared indirectly through their shared comparisons, so it can produce a full ranking rather than a scatter of separate results.
Measured against a waitlist, several classes worked. Among drugs, monoamine oxidase inhibitors (standardised mean difference -1.01, 95% credible interval -1.56 to -0.45), benzodiazepines (-0.96), SSRIs and SNRIs (-0.91) and anticonvulsants (-0.81) all beat the waitlist [s1]. Among talking therapies, individual CBT led with an SMD of -1.19 (95% CrI -1.56 to -0.81), followed by group CBT (-0.92), exposure and social skills training (-0.86), supported self-help (-0.86), unsupported self-help (-0.75) and psychodynamic psychotherapy (-0.62) [s1]. Larger negative numbers mean bigger symptom reductions.
Why the placebo comparison matters
Beating a waitlist is a low bar: people improve simply from being enrolled, monitored and expecting help. The more demanding test is whether a treatment beats a convincing placebo, and here the field thinned out fast. Only two classes cleared it — individual CBT against a psychological placebo (SMD -0.56, 95% CrI -1.00 to -0.11) and SSRIs and SNRIs against a pill placebo (-0.44, -0.67 to -0.22) [s1]. Individual CBT also outperformed psychodynamic psychotherapy (-0.56) and a group of interpersonal, mindfulness and supportive therapies (-0.82) [s1].
That pattern drove the authors' conclusion: individual CBT, which carries a lower risk of side effects than medication, should be regarded as the best first treatment for social anxiety disorder, and for people who decline therapy, SSRIs show the most consistent evidence of benefit [s1]. It is worth being clear about what did not clear the placebo bar. Benzodiazepines produced a large effect against a waitlist (SMD -0.96) but were not among the classes shown to beat a credible placebo, and they carry dependence risks that make them a poor fit for a chronic condition [s1]. A big waitlist effect, in other words, is not the same as a treatment that has proven its worth against expectation and attention.
A sober note on size
A second, independent meta-analysis is a useful reality check. A 2018 synthesis of 41 randomised placebo-controlled trials of CBT across anxiety disorders (2,843 patients) found a moderate overall effect on target symptoms (Hedges' g = 0.56) and a response rate roughly three times that of placebo (odds ratio 2.97) [s2]. But it also broke the results down by disorder, and social anxiety landed in the small-to-moderate range rather than the large one, alongside PTSD and panic [s2]. Its authors were blunt that more effective treatments are especially needed for those three conditions [s2]. One detail points to what carries the effect: interventions built mainly on exposure had larger effect sizes than those relying on cognitive techniques, although the difference was not statistically significant [s2].
What it means
For someone deciding what to try, the evidence supports a clear order of preference without pretending the results are miraculous. Individual, exposure-based CBT is the best-supported starting point; an SSRI is the best-supported alternative for anyone who would rather not do therapy or cannot access it; and combining or sequencing them is reasonable when one is not enough [s1]. The honest caveat is that even the winner produces a moderate effect, not a cure, and a meaningful share of people stay symptomatic after a full course [s2].
Social anxiety disorder is genuinely treatable, which is the part worth holding onto: it is not shyness you are meant to simply outgrow, and the interventions with the best evidence are widely used. Anyone whose anxiety is shrinking their life — or who is having thoughts of self-harm — should speak to a GP or a mental health professional, who can match a treatment to the specifics. This article describes evidence and is not medical advice.
Sources
- Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis — The Lancet Psychiatry, 2014-10-07
- Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials — Depression and Anxiety, 2018-02-16
Sources
- Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis — The Lancet Psychiatry , October 7, 2014
- Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials — Depression and Anxiety , February 16, 2018
More on
What helps panic attacks? The therapy with the most evidence, and its limits
A Cochrane network meta-analysis compared eight talking therapies for panic disorder. Cognitive behavioural therapy came out ahead most often — but the effects were small and the evidence graded low throughout.
What helps OCD and intrusive thoughts? The evidence favours a specific therapy
A network meta-analysis of 54 trials put behavioural and cognitive therapies ahead of the drugs on OCD symptoms. But most therapy trials also allowed antidepressants, hinting the two work best together.
Anxiety cases rose 50% in three decades. The age-standardised rate did not move.
The Global Burden of Disease estimates for anxiety disorders separate two things that public debate keeps merging: how many people have it, and how likely a given person is to. Diagnosis is a third question again.
Eight weeks of mindfulness matched a first-line anxiety drug in a randomised trial
The TAME trial randomised 276 adults with diagnosed anxiety disorders to mindfulness-based stress reduction or escitalopram. The difference on the primary measure was 0.07 points, inside the noninferiority margin.